Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.
Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.
With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.
Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.
Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.
Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced a $20 million commitment to enhance its Corporate Social Responsibility (CSR) program in the U.S. during its first year. The program focuses on health equity, climate resiliency, K-8 math literacy, and food security, partnering with 20 grant recipients who will share $16.6 million in total grants. The initiative aims to alleviate social disparities and improve overall community well-being across various sectors.
Takeda Pharmaceutical Company Limited announced FDA approval for LIVTENCITY™ (maribavir), the first treatment for adults and pediatric patients (12 years and older) with post-transplant cytomegalovirus (CMV) infection refractory to conventional therapies. In the Phase 3 SOLSTICE study, 56% of patients on LIVTENCITY achieved CMV DNA levels
Takeda Pharmaceutical Company Limited (NYSE: TAK) has announced new policy recommendations aimed at improving care for patients with rare diseases. This initiative includes three primary reforms focused on enhancing access to genetic screenings and specialized care, as well as improving data standardization. A recent Morning Consult survey revealed that two-thirds of voters lack understanding of rare diseases, emphasizing the need for greater awareness. Takeda's report aims to address significant barriers to timely diagnoses and treatment, which currently average six years from symptom onset.
Takeda Pharmaceutical Company applied for selection to the Prime Market of the Tokyo Stock Exchange (TSE). The decision was made during the Board of Directors Meeting on September 29-30, 2021, following the TSE's initial assessment on July 9, 2021, confirming compliance with listing requirements. The company also submitted its Corporate Governance Report based on an updated governance code. Enhancements to governance transparency include updated documents available on its corporate website. This move aims to maximize corporate value and strengthen stakeholder engagement.
Takeda Pharmaceutical Company announced a share buyback plan of up to 100 billion yen, aiming to acquire up to 35 million shares, representing 2.23% of outstanding shares. The initiative is designed to enhance capital efficiency and improve shareholder returns, indicating confidence in the company's cash generation capabilities. The buyback is scheduled from November 2, 2021 to April 29, 2022 and will not affect Takeda's existing deleveraging goals. The company's strong pipeline includes approximately 40 new molecular entities.
Takeda Pharmaceutical Company (NYSE:TAK) reported impressive financial results for H1 FY2021, with a 12.8% increase in reported revenue, amounting to 1,794.4 billion yen ($16.1B), and a 6.8% rise in underlying revenue of 1,661.4 billion yen ($14.9B). The company confirmed its full-year guidance aiming for a 30% core operating profit margin. Further growth is expected through its 14 global brands, which contributed 42% of total core revenue, and a share buyback of up to 100 billion yen highlights confidence in business strategy.
Takeda Pharmaceutical Company has announced its acquisition of GammaDelta Therapeutics, a biotech focused on γδ T cell immunotherapy. This strategic move expands Takeda's capabilities in the immuno-oncology space, targeting solid tumors and blood cancers. The acquisition follows a successful collaboration established in 2017 and involves pre-negotiated upfront and milestone payments. With a focus on off-the-shelf therapies, Takeda aims to enhance patient access to innovative cancer treatments. The deal is set to finalize in Q1 of Takeda's fiscal year 2022, pending regulatory review.
BioLife Plasma Services has opened its first plasma donation center in Worcester, Massachusetts, aiming to meet the urgent demand for plasma-derived therapies for rare and chronic conditions. This center is part of a growing network that currently includes over 160 centers across the U.S. BioLife plans to open additional centers, contributing $2-3 million annually to local communities and creating around 70 jobs per location. The center will begin operations on October 16, with an emphasis on providing an industry-leading donor experience.
Takeda announced that the FDA's Antimicrobial Drugs Advisory Committee unanimously recommended maribavir (TAK-620) for treating refractory cytomegalovirus (CMV) infections in transplant recipients. If approved, maribavir will be the first treatment indicated for adults with this condition. The recommendation is based on results from the Phase 2 and Phase 3 TAK-620-303 (SOLSTICE) trials. The FDA is currently conducting a Priority Review of the New Drug Application (NDA) for maribavir, which has also received Breakthrough Therapy and Orphan Drug designations.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced the suspension of patient dosing in its Phase 2 studies of TAK-994, an investigational oral orexin agonist, due to a safety signal. This premature cessation aims to reassess the treatment’s benefit/risk profile. Takeda remains committed to patient safety and plans to evaluate all available data for future development decisions regarding TAK-994. The company continues its focus on its orexin franchise, including TAK-861, which is in Phase 1 development.
FAQ
What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What are Takeda Pharmaceutical's core therapeutic areas?
Where is Takeda Pharmaceutical headquartered?
What recent collaborations has Takeda Pharmaceutical entered into?
How diversified is Takeda's revenue geographically?
What was Takeda's revenue in fiscal 2023?
Who can benefit from Takeda's new drug NBI-1065845?
What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?
How long has Takeda been in the pharmaceutical industry?
In how many countries does Takeda operate?
How does Takeda contribute to the field of major depressive disorder treatment?
